Sutro Biopharma (STRO)
(Delayed Data from NSDQ)
$5.01 USD
+0.46 (10.11%)
Updated Aug 23, 2024 04:00 PM ET
After-Market: $4.99 -0.02 (-0.40%) 7:58 PM ET
3-Hold of 5 3
D Value B Growth A Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$5.01 USD
+0.46 (10.11%)
Updated Aug 23, 2024 04:00 PM ET
After-Market: $4.99 -0.02 (-0.40%) 7:58 PM ET
3-Hold of 5 3
D Value B Growth A Momentum B VGM
Zacks News
Sutro Biopharma, Inc. (STRO) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
Sutro Biopharma, Inc. (STRO) delivered earnings and revenue surprises of 0.00% and -3.74%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Sutro Biopharma, Inc. (STRO) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Sutro Biopharma, Inc. (STRO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Sutro (STRO) Ovarian Cancer Drug Gets FDA's Fast Track Tag
by Zacks Equity Research
Sutro's (STRO) investigational antibody-drug conjugate therapy, STRO-002, gets Fast Track designation from the FDA for advanced ovarian cancer.
Sutro Biopharma, Inc. (STRO) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Sutro Biopharma, Inc. (STRO) delivered earnings and revenue surprises of 69.05% and 103.25%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Will Sutro Biopharma, Inc. (STRO) Report Negative Q2 Earnings? What You Should Know
by Zacks Equity Research
Sutro Biopharma, Inc. (STRO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Sutro Biopharma, Inc. (STRO) Surges 6.4%: Is This an Indication of Further Gains?
by Zacks Equity Research
Sutro Biopharma, Inc. (STRO) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Sutro Biopharma, Inc. (STRO) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Sutro Biopharma, Inc. (STRO) delivered earnings and revenue surprises of 29.51% and 111.97%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Sutro Biopharma, Inc. (STRO) Reports Q4 Loss, Lags Revenue Estimates
by Zacks Equity Research
Sutro Biopharma, Inc. (STRO) delivered earnings and revenue surprises of -164.29% and -32.13%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
Why Sutro Biopharma (STRO) Might Surprise This Earnings Season
by Zacks Equity Research
Sutro Biopharma (STRO) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Sutro Biopharma, Inc. (STRO) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release
by Zacks Equity Research
Sutro Biopharma, Inc. (STRO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Sutro Biopharma, Inc. (STRO) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Sutro Biopharma, Inc. (STRO) delivered earnings and revenue surprises of -1.69% and 7.66%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Will Sutro Biopharma, Inc. (STRO) Report Negative Q2 Earnings? What You Should Know
by Zacks Equity Research
Sutro Biopharma, Inc. (STRO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Will Sutro Biopharma Continue to Surge Higher?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor Sutro Biopharma
Sutro Biopharma, Inc. (STRO) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Sutro Biopharma, Inc. (STRO) delivered earnings and revenue surprises of 16.88% and 21.22%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?